ライフサイエンスコーパス: effector cell

1 re with the binding and interaction with the effector cell.

2 -modulation of beta-islet antigen-specific T effector cells.

3 ents presented with increased sensitivity of effector cells.

4 L activities as well as CD107a expression of effector cells.

5 g an immune reaction to form a large pool of effector cells.

6 ecific delivery of a rho kinase inhibitor to effector cells.

7 gulating the anticancer activities of immune effector cells.

8 vative (PPD)-driven peripheral blood-derived effector cells.

9 ctive CD4 T cells to IFN-gamma-producing CHS effector cells.

10 actions with different populations of immune effector cells.

11 d PD-1, consistent with the profile of acute effector cells.

12 lls to the cytotoxic effects of human immune effector cells.

13 d IL-17- or IFN-gamma-producing gammadelta T effector cells.

14 ffector memory and terminally differentiated effector cells.

15 stinguishes potential memory precursors from effector cells.

16 signature is only detectable in blood CD4(+) effector cells.

17 e detection of CARs on the surface of immune effector cells.

18 n and differentiate into distinct classes of effector cells.

19 ive phosphorylation typical for inflammatory effector cells.

20 esence of activated macrophages and Th1/Th17 effector cells.

21 ells into inflammatory IFN-gamma-coproducing effector cells.

22 thin the phagolysosome and in the cytosol of effector cells.

23 gesting an important role for macrophages as effector cells.

24 rare, antigen-specific T lymphocytes to form effector cells.

25 rise to IL-7-responsive polyfunctional CD4+ effector cells.

26 silonRI-bound IgE on the surface of allergic effector cells.

27 oxp3 expression to become IL-4-producing TH2 effector cells.

28 cells isolated from normal donors served as effector cells.

29 ession of CCR4 in circulating Treg but not T effector cells.

30 exposed, tolerance-prone RTEs into competent effector cells.

31 c cascade after crosslinking of receptors on effector cells.

32 gnant cells and direct stimulation of immune effector cells.

33 characterized as host defense antibacterial effector cells.

34 ls, monocytes, neutrophil trafficking, and T effector cells.

35 immunological memory cells and inefficient T effector cells.

36 -mediated cancer immunotherapy and improve T effector cell accumulation in the tumor microenvironment

37 duce tumor necrosis factor (TNF)-alpha, post-effector cells acquire innate signatures to adopt regula

38 The extent of effector cell activation is linked to allergen affinity,

39 port that FcgammaRIIB-mediated inhibition of effector cell activation requires direct ligation to an

40 Analyses of effector cell activation revealed that ligelizumab inhib

41 ent class ( e.g., IgE) could engender potent effector cell activation, and unleash previously untappe

42 nity and oligomeric state on IgE binding and effector cell activation.

43 conditions, antibodies can bridge an immune effector cell and an antigen-presenting cell, implying t

44 called by restimulation, analogous to T-cell effector cell and memory cell generation.

45 rized by a CD4 T cell differentiation toward effector cells and by a lower frequency of IFN-gamma pro

46 The variety of potential effector cells and cancer Ags, along with potential comb

47 Suppressive capacity of Tregs on effector cells and cytokines was assessed.

48 llografts have suppression of alloreactive T effector cells and delayed acute rejection.

49 uced by pathogen-specific CD8(+) and CD4(+)T effector cells and delineated several unique properties

50 educed by restricting IL-6Ra deficiency to T effector cells and excluding Tregs.

51 r (FcgammaR)-mediated signalling pathways in effector cells and five mAbs possessed NA inhibition act

52 ptor FcgammaRIIB is co-expressed on allergic effector cells and has been implicated in negative regul

53 f intratumoral but not systemic Tregs into T effector cells and leads to enhanced antitumor immunity.

54 Antibody secreting cells (ASCs) are critical effector cells and long-lived sentinels for immune memor

55 Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antige

56 n during bacterial infection, acting as both effector cells and regulators of neutrophil recruitment

57 +) T cell produces terminally differentiated effector cells and renews itself for continued defense.

58 aRIIB with FcepsilonRI-bound IgE on allergic effector cells and represents an efficient dual-modality

59 including the central role of innate immune effector cells and subsequent inflammatory cascades in p

60 ooperative and/or inhibitory interplay among effector cells and their impact on RANKL/OPG balance and

61 n cancer cells) and indirect (through immune effector cells and vasculature) effects on the tumour.

62 nderstanding the interactions between innate effector cells and virus-specific antibodies.

63 phages were not cleared by pulmonary immune effector cells and were immunologically well tolerated b

64 cessive mechanisms leading to elimination of effector cells and, simultaneously, a dominant mechanism

65 olate keratinocytes, dendritic cells, CD4+ T effector cells, and CD8+ T effector cells from healthy s

66 cytokine/chemokine production from allergic effector cells, and did not elicit allergic reactivity i

67 e of invading pathogens in infected cells to effector cells, and in interfering with processes essent

68 the roles of IgE and IgG antibodies, immune effector cells, and mediators thought to contribute to e

69 describes the observation that innate immune effector cells appear to be differentially recruited to

70 Whereas these mature effector cells are extensively studied, the differentiat

71 his mouse strain, suggesting either that the effector cells are present in greater numbers within dys

72 in DNA methylation programming at naive and effector cell-associated genes in virus-specific CD8 T c

73 nt-associated adverse events, such as immune effector cell-associated neurotoxicity syndrome (ICANS),

74 s cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

75 py such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and acu

76 duces targeted cell lysis in the presence of effector cells at as low as sub-picomolar concentrations

77 cted macrophages co-cultured with PPD-driven effector cells at physiologically relevant concentration

78 sis to favor the production of innate immune effector cells at the expense of lymphoid cells and eryt

79 ution to immunity of major subsets of immune effector cells (B cells, CD4(+) and CD8(+) T cells) in a

80 d role for macrophages as anti-mycobacterial effector cells, badger macrophage (bdMphi) responses rem

81 -party donors may offer ideal fitness of the effector cells, but carry the risk of graft-versus-host

82 nge from dysfunction to differentiation into effector cells, but the mechanisms that underlie these d

83 T cells differentiated into potent cytotoxic effector cells by 10 wk of age, despite their fetal orig

84 and adaptive immunity through activation of effector cells by antigen-antibody complexes.

85 ation of terminally mature functional innate effector cells can be elucidated.

86 These effector cells can potentially influence many disease st

87 ntiation resulted in acquisition of terminal effector cell characteristics, whereas enhancement of pr

88 in the CXCR3 axis drives both the anti-tumor effector cell chemoattraction and pro-tumor infiltration

89 iate vascular leak, bronchoconstriction, and effector cell chemotaxis.

90 and other Ab-dependent activation of myeloid effector cells, close cell-cell contact (between effecto

91 f synovial stromal cells into autoaggressive effector cells converts synovitis from acute to chronic

92 Proliferating casein/T-effector cell counts were measured in children with CM-F

93 ers are required to stimulate high levels of effector cell degranulation when using the humanized RBL

94 Removal of sialic acid from IgE attenuates effector-cell degranulation and anaphylaxis in several f

95 B and T cells are important effector cells delaying the spread of pneumococci from t

96 required destination, and differentiate into effector cells, depending on the local tissue environmen

97 poised to quickly develop into regulatory or effector cells, depending on the needs of the host.

98 naive T cells to differentiate into various effector cells, determining immune responses such as all

99 ty to provide long-term immunity while other effector cells develop into terminally differentiated ef

100 rexpression or knockdown of PP2Ac in human T effector cells did not affect IL-2-dependent pSTAT5 acti

101 nhibition of Foxp3 expression in response to effector cell-differentiating cytokines.

102 everal junctures of B lineage maturation and effector cell differentiation by controlling B cell acti

103 parts that require peripheral activation for effector cell differentiation, gammadelta T cells instea

104 innate lymphoid cells (ILC2s) are important effector cells driving the initiation of type 2 immune r

105 have been suggested as the anti-inflammatory effector cells during helminth infections.

106 during homeostasis, but can be potent immune effector cells during inflammation.

107 f the Nfia gene normally differentiated into effector cells during sepsis, cleared infecting bacteria

108 arise from their differentiation into mature effector cells during thymic development.

109 natively activated macrophages are essential effector cells during type 2 immunity and tissue repair

110 cytokine production of immune and epithelial effector cells during type 2 inflammation.

111 differentiation after priming, termed "early effector cells" (EEC), which also exhibited an activated

112 lineating the effect of complement-dependent effector-cell engagement in various therapeutic settings

113 onverted from suppressor cells to pathogenic effector cells, enhancing lung allergic responses, but t

114 latory T (iTreg) cells can become pathogenic effector cells, enhancing lung allergic responses.

115 ll development, homeostasis, activation, and effector-cell fate decisions, as well as its important i

116 tiation, regulated the formation of terminal-effector cell fates and memory-precursor cell fates, res

117 ion and/or rapid attrition of functional CAR effector cells following adoptive transfer.

118 to increased activation and proliferation of effector cells following stimulation and antigen recogni

119 Macrophages are also the key effector cell for mAb therapies.

120 tic cells, CD4+ T effector cells, and CD8+ T effector cells from healthy skin samples, followed by RN

121 mory cells embody features of both naive and effector cells, fuelling a long-standing debate centred

122 CD4(+)FOXP3(+) Tregs in vivo and suppressing effector cell function and could be the basis of effecti

123 Nevertheless, additional investigations into effector cell function between KS and asymptomatic indiv

124 IFN-alpha treatments for the enhancement of effector cell function in HIV(+) patients in future cure

125 including autoreactive B cell activation, T effector cell function in target tissues, and type I IFN

126 gy will probably depend on enhancing patient effector cell function.

127 o impaired cytokine production and/cytotoxic effector cell function.

128 inths have been previously shown to suppress effector cell function; however, their ability to treat

129 nflammatory protein that potently suppresses effector cell functions in eosinophils.

130 d-endothelial cell (EC) barrier and exerting effector cell functions.

131 study, we defined the bioenergetics of Th17 effector cells generated in vivo.

132 es memory T cells, CCR4 supports short-lived effector cell generation.

133 results in enhanced differentiation towards effector cells, glycolysis and apoptosis.

134 on of T-bet, a characteristic of short-lived effector cells, GW-treated cells demonstrated enhanced p

135 T cells can have features of both naive and effector cells has forced the field to struggle with sev

136 atosus, plasmacytoid dendritic cells are not effector cells, have lost capacity for Toll-like-recepto

137 lls and produce IgE immunoglobulins that arm effector cells; however, mouse models are inconclusive o

138 ILC2) are tissue-resident, long-lived innate effector cells implicated in allergy and asthma.

139 chlamydia and establish neutrophils as a key effector cell in this response.

140 Beyond their historical role as the effector cells in allergic disorders, mast cells have be

141 Mast cells (MCs) are central effector cells in allergic reactions that are often medi

142 Mast cells are key effector cells in allergic reactions.

143 come potent, steroid-insensitive, pathogenic effector cells in asthmatic patients and in mice in a mo

144 e functions of IgE antibodies and associated effector cells in both antitumour immune surveillance an

145 CD8-expressing T cells are the main effector cells in cancer immunotherapy.

146 t platelets are critical thromboinflammatory effector cells in CF lung disease.

147 is study highlights the importance of innate effector cells in establishing a broad-spectrum antivira

148 Platelets are the chief effector cells in hemostasis.

149 t neutrophils and gammadelta T cells are key effector cells in IL-23-mediated skin and joint inflamma

150 ing eosinophils as predictive biomarkers and effector cells in immunotherapy, especially in response

151 Neutrophils are key effector cells in inflammation and play an important rol

152 D8(+) T cells to differentiate into terminal effector cells in response to microbial infection.

153 Activated fibroblasts are the key effector cells in SSc responsible for the excessive prod

154 nt is accompanied by decreases in numbers of effector cells in target organs, including mast cells, b

155 Natural killer (NK) cells are important effector cells in the immune response to cancer.

156 m formation is to allow persistence of CD8 T effector cells in the lung as they transition to Trm.

157 B cells contributed also to expansion of TH2 effector cells in the lungs and central memory T cells i

158 ciated with proliferation of recipient CD8 T effector cells in the periphery and liver, increased ser

159 Increasing the incubation of target and effector cells in the presence of mAb combinations from

160 thogenic site, the gut, and retained these T effector cells in the systemic sites, leading to augment

161 d by few malignant cells and numerous immune effector cells in the tumour microenvironment.

162 fected target cells by HIV-1-specific CD8(+) effector cells in vitro Among persons expressing protect

163 and differentiated readily into Ag-specific effector cells in vitro.

164 urvival in vitro and survival of short-lived effector cells in vivo in response to Listeria monocytog

165 xicity (ADCC) in vitro resulted in arming of effector cells in vivo, yet led to viral-decay kinetics

166 or CD16 (also known as FcgRIII) of an immune effector cell, in a quasi-bidimensional environment (2D)

167 16a N-glycan composition in CD16a-expressing effector cells including NK cells may improve treatment

168 dies suggest that Fc-dependent activation of effector cells, including NK cells, could play a role in

169 that HBZ expression in Jurkat cells (used as effector cells) increases HTLV-1 infection.

170 to allergens, for example, by desensitizing effector cells, inducing regulatory T and B lymphocytes

171 abnormal and dysfunctional and, thus, immune effector cell infiltration is impaired.

172 a model for the differentiation of terminal effector cells initiated by an early burst of transcript

173 ICAM-1, on the surface of the infected cell (effector cell) initiates and stabilizes cell-cell contac

174 phils and show the importance of an antibody/effector cell interaction in mediating humoral immunity.

175 Appropriate migration of cytotoxic T effector cells into the tumors is crucial for their anti

176 by T helper 17 (TH17) cells (CD4(+) T helper effector cells involved in multiple inflammatory conditi

177 Basophils are important effector cells involved in the pathogenesis of inflammat

178 rapy of cancer, expansion and persistence of effector cells is a key determinant of response.

179 ncode processing enzymes in CD16a-expressing effector cells is sufficient to affect N-glycan composit

180 ial activity of the host immune response via effector cells, like macrophages and neutrophils.

181 se and that these T cells (termed long-lived effector cells [LLEC]) display robust protective functio

182 We also find that in contrast to KLRG1(+) effector cells, LLEC undergo homeostatic proliferation a

183 stream differentiation marker and downstream effector cell marker) of IL-9 upregulation only in Afric

184 driver of Th1 differentiation and cytotoxic effector cell maturation.

185 induce direct apoptosis and activate immune effector cells may provide benefit over existing treatme

186 Propionate suppressed T effector cell migration between the intestine and the sp

187 These cells may derive from memory precursor effector cells (MPECs), which are distinct from short-li

188 These data suggest that tissue resident effector cell numbers and low FcgammaR expression may li

189 anti-PD-1 Ab treatment did not alter immune effector cell numbers or myeloid cell activation.

190 Mast cells (MCs), the primary effector cell of the atopic response, participate in imm

191 Mast cells (MCs) are best known as key effector cells of allergic reactions, but they also play

192 ally, at a cellular level, MCs act as potent effector cells of complement activation by expressing re

193 aptive responses of cardiac fibroblasts, the effector cells of fibrosis in the heart.

194 EMT-driven generation of myofibroblasts, the effector cells of fibrosis that produce excessive extrac

195 Platelets are chief effector cells of hemostasis and pathological thrombosis

196 Natural killer (NK) cells are key effector cells of innate resistance capable of destroyin

197 n to their role in milk production, they are effector cells of mammary immunity.

198 paradigm that microglia are the main immune effector cells of the CNS.

199 ucleated cells are continuously monitored by effector cells of the immune system, which police the pe

200 irect the clearance of HIV-infected cells by effector cells of the immune system.

201 Neutrophils are key effector cells of the innate immune system.

202 macrophages (Ccr2 (RFP/RFP)), microglia are effector cells of tumor cell phagocytosis in response to

203 Group 2 innate lymphoid cells (ILC2s) are effector cells of type 2 immune responses that also expr

204 or producers of eicosanoids and they are key effector cells of type 2 immunity.

205 Possessing specificity for effector cells on one end and a tumor Ag on the other, t

206 direct cell killing in the absence of immune effector cells or complement via a proinflammatory mecha

207 ntred on whether memory T cells develop from effector cells or directly from naive cells.

208 cient in the antibodies, antibody receptors, effector cells, or mediators implicated in anaphylaxis a

209 vity against allergens through activation of effector cells, particularly mast cells (MCs).

210 and proinflammatory genes consistent with an effector cell phenotype, whereas donor-origin T cells ap

211 Similarly, elevated T effector cell polarization within blood and brain tissue

212 contribute significantly to the ADCC-capable effector cell pool in patients on antiretroviral therapy

213 ng growth factor beta levels, decreasing the effector cell population and increasing the T-regulatory

214 support the view that an IFN-gamma-activated effector cell population cooperates with antibody to pro

215 T lymphocytes constitute a major effector cell population in autoimmune type 1 diabetes.

216 od myeloid mononuclear cells represent a key effector cell population in this model of virus-induced

217 ncluding a Blimp1(hi)Id3(lo) tissue-resident effector cell population most prominent in the early pha

218 e memory population or are instead a remnant effector cell population that failed to undergo initial

219 reviously unappreciated IL-10 producing ILC2 effector cell population.

220 onses were favored by high concentrations of effector cells postinjection, such as induced by higher

221 er enhanced immune surveillance and superior effector cell potency against cancer cells.

222 potentially fatal condition in which allergy effector cells rapidly discharge pre-formed inflammatory

223 to carry out ADCP in settings of high target/effector cell ratios, such as those seen in patients wit

224 rrying the S239D/I332E mutation for improved effector cell recruitment (CD19-DE).

225 ducted, we considered and calibrated a tumor-effector cell recruitment model under the influence of f

226 Due to their ability to suppress effector cells, regulatory T cells (Tregs) have been pro

227 PKCeta in protective immunity mediated by T effector cells remains unclear.

228 streptavidin (SA-PDL1) that inhibited the T effector cell response to alloantigens and converted T c

229 Myofibroblasts are the key effector cells responsible for excessive extracellular m

230 for optimal protection; however, the innate effector cells responsible for mediating this protection

231 ink IgE bound to its receptor FcepsilonRI on effector cells, resulting in cell degranulation and rele

232 amplified and sustained polyfunctional CD4+ effector cells, resulting in improved therapeutic outcom

233 tifibrotic efficacy or the identity of their effector cell(s).

234 Th1 effector cells selectively drive CF both in vitro and in

235 The anti-IgE autoantibodies prevented effector cell sensitization, reduced total IgE serum lev

236 immune cells tested, activated human CD8(+) effector cells showed the highest accumulation of [18F]F

237 vity diseases by activating degranulation of effector cells such as mast cells and basophils.

238 c mutations also give rise to mutated immune effector cells, such as monocytes, granulocytes, and lym

239 nfected CD4+ T cells by recruiting cytotoxic effector cells, such as natural killer cells, monocytes,

240 share many features with other innate immune effector cells, such as neutrophils and macrophages, the

241 ce T(H)17 response at the expense of other T effector cells (T(EFF)), particularly T(H)1.

242 at result in cytokine production in CD4(+) T effector cells (Teff).

243 lymphocytes, enhanced the polarization of T effector cells (TH1/TH17), and decreased the production

244 suppression was more pronounced in terminal effector cells than in memory precursor cells and was re

245 ertoires including late stage NKG2A(-)KIR(+) effector cells that are commonly not generated from prev

246 hoid cells (ILC2) are tissue-resident innate effector cells that can mediate airway inflammation and

247 Eosinophils are then the critical effector cells that cause pathology.

248 On their exit to the periphery, T cells are effector cells that control infections or regulatory cel

249 dered neutrophils to function as nonspecific effector cells that die quickly after performing antimic

250 ds to differentiation of CD8(+) T cells into effector cells that form dense, extravascular clusters o

251 be combined to recruit and reprogram immune effector cells that have the capacity to fulfill complex

252 le for neutrophils in the liver as resolving effector cells that induce pro-inflammatory macrophages

253 al killer (NK) cells are important antiviral effector cells that likely encounter RSV in the presence

254 Neutrophils are key effector cells that orchestrate inflammatory responses i

255 (MPECs), which are distinct from short-lived effector cells that provide acute protection but are oft

256 Neutrophils are innate immune effector cells that traffic from the circulation to extr

257 On the side of the effector cell, the FcgammaRIIIa-Val/Phe158 polymorphism

258 s favored differentiation into memory versus effector cells, the former of which are superior in medi

259 stration of monoclonal antibodies and immune effector cell therapies.

260 8(+) T cells but not to differentiation into effector cells; these cells form loose, intravascular cl

261 e of an extremely high number of circulating effector cells, thought to be necessary to scan, locate,

262 natorial IVT to recruit and reprogram immune effector cells to acquire divergent biological functions

263 of mechanical stimulation to coordinate with effector cells to adjust bone mass, size, and shape to c

264 strategies to recruit and redirect cytotoxic effector cells to eliminate the HIV-1 latently infected

265 its differentiation intermediates and mature effector cells to expand upon demand, thereby providing

266 also have the potential to guide host immune effector cells to kill HIV-1-infected cells.

267 and paracrine signaling loops that can alert effector cells to sites of infection but also provides a

268 firmed by exposing in vitro different immune effector cells to the action of primary hAECs.

269 t lymphoma cytotoxicity and activates immune effector cells, to the anti-CD20 antibody (alphaCD20-IL-

270 ntroduce pre-mNK cells as a novel downstream effector cell type whose anticancer properties may have

271 We also discuss various inflammatory effector cell types involved in cytokine production, rem

272 Both effector cell types use multiple strategies to induce ta

273 SNP-IV proliferated and differentiated into effector cells upon checkpoint blockade, leading to supe

274 ong-lived and can rapidly differentiate into effector cells upon inflammatory antigenic challenge.

275 MSCs affect the functions of most immune effector cells via direct contact with immune cells and

276 geting the surface-bound IgE of the allergic effector cells via low-affinity anti-human IgE Abs with

277 -inducing condition where activated CD4(+) T effector cells were converted to Foxp3+ Tregs, we tested

278 The effects of EV's action on DTH effector cells were evaluated cytometrically.

279 Effector cells were evaluated using in vitro human cell

280 Effector cells were evaluated with in vitro human cell c

281 c hepatitis B patients became polyfunctional effector cells when grafted with HBV-specific TCRs and e

282 LLEC are predominantly derived from KLRG1(+) effector cells when isolated at day 12 of the response.

283 from trained mice are more potent antitumor effector cells when transferred into tumor-bearing untra

284 rogression in activated naive cells, but not effector cells, whereas metabolism was consistently impa

285 HSCs are key effector cells which maintain the composition of the ECM

286 expressing specific antibody isotypes, or T effector cells, which activate microbicidal innate cells

287 4 T cells undergo transcriptional changes to effector cells, which are commonly dysregulated in autoi

288 ocal fate decisions between iNKT1 and iNKT17 effector cells, which respectively depend upon mitochond

289 two years of SLIT was the desensitization of effector cells, which was only detected in Mono-sensitiz

290 inflammation through FcepsilonRI on allergic effector cells, while IgE-ICs were noninflammatory becau

291 atural killer (NK) cells are critical innate effector cells whose development is dependent on the Jan

292 Macrophages are potent immune effector cells whose functional plasticity leads to anti

293 D8(+) T cells are reprogrammed to long-lived effector cells with extensive accumulation, better persi

294 Stimulation of effector cells with IL-2 downregulated mRNA expression o

295 Furthermore, the treatment of DTH effector cells with sMRBC-induced EVs decreased the acti

296 ppress the proliferation of FVIII-specific T-effector cells with specificity for a different FVIII do

297 ferentiation is set to produce myriad immune effector cells with the ability to respond to multitudin

298 d tissue-resident ILC progenitors (ILCP) and effector-cells with heterogeneous expression of the tran

299 lation of TH1-type CD4(+) T cells and immune effector cells within affected organs, most frequently t

300 Group 2 innate lymphoid cells (ILC2s) are effector cells within the mucosa and key participants in